Peter F. Thall

24.0k total citations · 1 hit paper
338 papers, 14.3k citations indexed

About

Peter F. Thall is a scholar working on Statistics and Probability, Hematology and Management Science and Operations Research. According to data from OpenAlex, Peter F. Thall has authored 338 papers receiving a total of 14.3k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Statistics and Probability, 93 papers in Hematology and 59 papers in Management Science and Operations Research. Recurrent topics in Peter F. Thall's work include Statistical Methods in Clinical Trials (139 papers), Optimal Experimental Design Methods (55 papers) and Acute Myeloid Leukemia Research (49 papers). Peter F. Thall is often cited by papers focused on Statistical Methods in Clinical Trials (139 papers), Optimal Experimental Design Methods (55 papers) and Acute Myeloid Leukemia Research (49 papers). Peter F. Thall collaborates with scholars based in United States, Canada and France. Peter F. Thall's co-authors include Elihu H. Estey, Richard E. Champlin, Richard Simon, J. Kyle Wathen, Xuemei Wang, John D. Cook, Hoang Q. Nguyen, Randall E. Millikan, Börje S. Andersson and Hagop M. Kantarjian and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American Statistical Association and Blood.

In The Last Decade

Peter F. Thall

329 papers receiving 13.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

2007 531 citations Robert G. Maki, J. Kyle Wathen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Peter F. Thall

Since Specialization

Citations

This map shows the geographic impact of Peter F. Thall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter F. Thall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter F. Thall more than expected).

Fields of papers citing papers by Peter F. Thall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter F. Thall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter F. Thall. The network helps show where Peter F. Thall may publish in the future.

Co-authorship network of co-authors of Peter F. Thall

This figure shows the co-authorship network connecting the top 25 collaborators of Peter F. Thall. A scholar is included among the top collaborators of Peter F. Thall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter F. Thall. Peter F. Thall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus 2024 ·Clinical Trials ·Peter F. Thall, Elizabeth Garrett‐Mayer, Nolan A. Wages, Susan Halabi, Ying Kuen Cheung	4
2	ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications 2024 ·Biometrics ·(unknown), Peter F. Thall, Kentaro Takeda, Ying Yuan	1
3	Generalized phase I‐II designs to increase long term therapeutic success rate 2023 ·Pharmaceutical Statistics ·Peter F. Thall, Yong Zang, Ying Yuan	5
4	BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials 2023 ·Clinical Trials ·Liyun Jiang, Peter F. Thall, Fangrong Yan, Scott Kopetz, Ying Yuan	5
5	A Bayesian piecewise exponential phase II design for monitoring a time‐to‐event endpoint 2022 ·Pharmaceutical Statistics ·Yun Qing, Peter F. Thall, Ying Yuan	0
6	Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers 2021 ·Biometrics ·Yeonhee Park, Suyu Liu, Peter F. Thall, Ying Yuan	12
7	Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer 2021 ·JCO Precision Oncology ·Rebecca S. Tidwell, Peter F. Thall, Ying Yuan	5
8	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients 2020 ·Blood Advances ·Betül Oran, Marcos de Lima, Guillermo Garcia‐Manero, Peter F. Thall, Ruitao Lin, Uday Popat, Amin M. Alousi, Chitra Hosing, Sergio Giralt, Gabriela Rondón, (unknown), Richard E. Champlin	132
9	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis 2020 ·Cancer ·Kristina R. Dahlstrom, Juhee Song, Peter F. Thall, Clifton D. Fuller, Katherine A. Hutcheson, Faye M. Johnson, G. Brandon Gunn, Jack Phan, Steven J. Frank, William H. Morrison, Renata Ferrarotto, David I. Rosenthal, Erich M. Sturgis, Adam S. Garden	3
10	An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes 2019 ·Biometrics ·Ruitao Lin, Peter F. Thall, Ying Yuan	14
11	Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation 2018 ·Clinical Cancer Research ·Jeff Davies, Lisa Brennan, John R. Wingard, Christopher R. Cogle, Neena Kapoor, Ami J. Shah, Bimalangshu R. Dey, Thomas R. Spitzer, Marcos de Lima, Laurence J.N. Cooper, Peter F. Thall, Richard E. Champlin, Lee M. Nadler, Eva C. Guinan	7
12	Subgroup‐specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination 2018 ·Pharmaceutical Statistics ·Andrew G. Chapple, Peter F. Thall	21
13	Bayesian treatment comparison using parametric mixture priors computed from elicited histograms 2017 ·Statistical Methods in Medical Research ·Peter F. Thall, Moreno Ursino, Véronique Baudouin, Corinne Alberti, Sarah Zohar	7
14	Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer 2013 ·Clinical Cancer Research ·Ana M. Aparicio, Andrea Harzstark, Paul G. Corn, Sijin Wen, John C. Araujo, Shi‐Ming Tu, Lance C. Pagliaro, Jeri Kim, Randall E. Millikan, Charles J. Ryan, Nizar M. Tannir, Amado J. Zurita, Paul Mathew, Wadih Arap, Patricia Troncoso, Peter F. Thall, Christopher J. Logothetis	311
15	Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes 2013 ·Biometrics ·Peter F. Thall, Hoang Q. Nguyen, Thomas Braun, Muzaffar H. Qazilbash	41
16	Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation 2011 ·Blood ·Stefan O. Ciurea, Peter F. Thall, Xuemei Wang, Sa A. Wang, (unknown), Pedro Cano, Fleur M. Aung, Gabriela Rondón, Jeffrey J. Molldrem, Martin Körbling, Elizabeth J. Shpall, Marcos de Lima, Richard E. Champlin, Marcelo Fernández-Viña	148
17	Association of Intratumoral Vascular Endothelial Growth Factor Expression and Clinical Outcome for Patients with Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate 2007 ·Clinical Cancer Research ·John C. McAuliffe, Alexander J. Lazar, Dan Yang, (unknown), Wei Qiao, Peter F. Thall, A. Kevin Raymond, Robert S. Benjamin, Jonathan C. Trent	33
18	Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002 breakdown → 2007 ·Journal of Clinical Oncology ·Robert G. Maki, J. Kyle Wathen, Shreyaskumar Patel, Dennis A. Priebat, Scott H. Okuno, Brian L. Samuels, Michael Fanucchi, David C. Harmon, Scott M. Schuetze, Denise K. Reinke, Peter F. Thall, Robert S. Benjamin, Laurence H. Baker, Martee L. Hensley	531
19	Variable Selection in Regression via Repeated Data Splitting 1997 ·Journal of Computational and Graphical Statistics ·Peter F. Thall, Kathy Russell, Richard Simon	10
20	Test-Based Variable Selection via Cross-Validation 1992 ·Journal of Computational and Graphical Statistics ·Peter F. Thall, Richard Simon, David Alan Grier	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact